

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**JD Health International Inc.**

**京东健康股份有限公司**

*(A company incorporated in the Cayman Islands with limited liability)*

**(Stock Codes: 6618 (HKD counter) and 86618 (RMB counter))**

## **INSIDE INFORMATION UNAUDITED UPDATE ON THE 2024 FIRST QUARTER**

This announcement is issued by JD Health International Inc. (the “**Company**” or “**JD Health**”, and together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

### **Business Update**

- During the first quarter of 2024, several new and specialty drugs debuted on JD Pharmacy, including NURTEC<sup>®</sup> (Rimegepant Sulfate Orally Disintegrating Tablets), a new targeted drug for migraine treatment developed by Pfizer, and ZENON<sup>®</sup> (Rosuvastatin Calcium and Ezetimibe Tablets), a new lipid-lowering combination drug developed by Sanofi. In addition, we continued to deepen our collaboration with, among others, Shanghai Pharmaceuticals, Daiichi Sankyo, and Sunshine Mandi Pharmaceutical, to further expand our partnered brands and product offerings through strengthened omnichannel cooperation, providing a wider selection and a better purchasing experience to our users.
- In January 2024, JD Health launched its “Elderly Health Care Channel” and continued to expand its product portfolio to better cater for the diverse home-based care needs of senior citizens. At present, our platform covers thousands of related subcategories with products from more than 30,000 brands. Meanwhile, JD Health has been consistently strengthening its integrated online and offline service capabilities to improve service efficiency and user experience. Building on our existing online offerings, including consultation services provided on JD Health Online Hospital (京東健康互聯網醫院) and health management product “Family Doctor” service for seniors, we will further diversify our at-home service offerings, including medical appointment companions, at-home testing, and home care services.

## Unaudited Financial Information

The Company is pleased to announce the unaudited revenue and operating income of the Group for the three months ended March 31, 2024 together with comparative figures for the corresponding period of 2023:

	Three months ended March 31,		Change (%)
	2024 RMB'000 (Unaudited)	2023 RMB'000 (Unaudited)	
Revenue	13,267,397	13,950,397	(4.9)
Operating income*	487,316	795,445	(38.7)
Non-IFRS operating income**	754,380	1,156,955	(34.8)

\* Operating income consists of gross profit deducting fulfillment expenses, selling and marketing expenses, research and development expenses, general and administrative expenses, and impairment losses under expected credit loss model, net of reversal.

\*\* We define “non-IFRS operating income” as operating income for the period, excluding share-based payment expenses for the period. We exclude this item because it is non-operating in nature, not indicative of our core operating results and business outlook, and it does not generate any cash outflows.

The above information is based on the board (the “**Board**”) of directors (the “**Directors**”) of the Company’s preliminary review of the internal data currently available and gathered by the Company only and is not intended to be a comprehensive statement of the Group’s financial result. The said information and data have not been audited or reviewed by the Company’s auditors and may be subject to change and adjustment.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**JD Health International Inc.**  
**Mr. Enlin Jin**  
*Executive Director*

Hong Kong, May 16, 2024

*As of the date of this announcement, the Board comprises Mr. Enlin Jin as the executive Director, Mr. Richard Qiangdong Liu and Mr. Qingqing Yi as non-executive Directors, and Ms. Ling Li, Dr. Jiyu Zhang, Mr. Xingyao Chen and Mr. Ying Wu as independent non-executive Directors.*